
SR-17018: A Potential Opioid Exit Banned by DEA
The Unfolding Saga of SR-17018: Hope and Halted Progress In the relentless shadow of the...
Tag archive

The Unfolding Saga of SR-17018: Hope and Halted Progress In the relentless shadow of the...
Mechanisms of AI in Medical Research Artificial intelligence (AI) is poised to...

Warp Sciences, led by ex-OpenAI product chief Kevin Weil, raised a $215M Series A at an $865M valuation to build AI and robot chemistry labs in the US.
SwarmRSI Hits the Spotlight: 2026’s First Open‑Ended Recursive Self‑Improvement...
Lead NeuroScale, the AI‑powered biotech startup, announced a $150 million Series C...

Insilico's rentosertib is the first medicine with both an AI-picked target and an AI-drawn molecule. Six independent aging clocks — built at Harvard, Oxford and Beijing — all agree it reversed patients' biological age. It's now in Phase III.

Bacteria evolve faster than we find new antibiotics. In 2026, ChatGPT and Codex started showing up in the search for new antimicrobial molecules — not as scientists, but as the coding and research layer around labs like Penn's Machine Biology Group.
A Nature Biotechnology reanalysis found six proteomic ageing clocks moved in the younger direction in treated IPF patients receiving Insilico’s AI-designed rentosertib, without proving rejuvenation in healthy people.
Stanford's AI swarm of 37,000 agents acts as a virtual biotech, delivering a Merck‑validated drug candidate. Learn how massive AI orchestration reshapes biotech.

In a wet lab, Claude autonomously invented protein binders that stuck to 14 of 15 targets — at twice the industry hit rate. Two labs confirmed it.

Phasecraft and NVIDIA recently announced a significant breakthrough in quantum simulation performance...
Anthropic said on August 18 that Claude designed minibinders against 15 protein targets and succeeded on 14, with hit rates of 26.7 and 22.6 percent against the 10 to 15 percent typical of protein design campaigns, validated by two independent contra